Years Ended March 31, | |||||||||||
(In millions) | 2013 | 2012 | 2011 | ||||||||
Operating Expenses | |||||||||||
Transaction closing expenses | $ | 16 | $ | 3 | $ | 22 | |||||
Restructuring, severance and relocation | 31 | 6 | 9 | ||||||||
Other integration related expenses | 25 | 22 | 12 | ||||||||
Gain on business combination | (81 | ) | — | — | |||||||
Total | (9 | ) | 31 | 43 | |||||||
Other Income: reimbursement of post-acquisition interest expense from former US Oncology shareholders | — | — | (16 | ) | |||||||
Interest Expense: bridge loan fees | 11 | — | 25 | ||||||||
Total Acquisition Expenses and Related Adjustments | $ | 2 | $ | 31 | $ | 52 | |||||